Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

UCB (UCBJF) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinson’s disease from Biotie Therapies.

The Candidate

Tozadenant is an orally administered, selective inhibitor of the adenosine 2a receptor, which is being developed for the treatment of Parkinson’s disease.

UCB’s decision to in-license the candidate was based on encouraging results from a double-blind, randomized, placebo-controlled phase IIb study that evaluated tozadenant as an adjunctive therapy in levodopa-treated Parkinson's disease patients. Phase III program will be conducted by Biotie for which patient enrolment will start by the first half of 2015.

Terms of the Deal

UCB and Biotie had initially announced their collaboration in 2010. However, with the in-licensing of tozadenant, the original agreement has been modified. Biotie will now receive an upfront payment of $20 million from UCB. Under the original agreement, Biotie was supposed to receive an additional $340 million on the achievement of future milestones. Under the revised deal, Biotie will receive additional amounts in the low triple-digit millions in total, over the next six years, on the achievement of defined development, regulatory and commercialization milestones. Both UCB and Biotie will work on the ongoing clinical development of this candidate. Manufacturing and commercialization of tozadenant will be handled by UCB.

Our Take

This licensing deal represents UCB’s efforts to strengthen its Parkinson’s disease portfolio. The company currently has Neupro in its portfolio for the symptomatic treatment of all stages of idiopathic Parkinson’s disease.

UCB carries a Zacks Rank #3 (Hold). Currently, companies like Lannett Company, Inc. (LCI - Snapshot Report), SIGA Technologies, Inc. (SIGA - Snapshot Report) and QLT Inc. (QLTI - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 29.85 +16.83%
ALLIANCE FIB AFOP 17.94 +3.59%
FEDERATED NA FNHC 20.51 +3.22%
GENTHERM INC THRM 36.80 +2.65%
ATLAS FINANC AFH 14.60 +2.53%